Financial Report: Abbott 2Q

Abbott 2Q

2Q Revenues: $7.5 billion (+3%)

2Q Earnings: $1.3 billion (-3%)

YTD Revenues: $14.2 billion (+1%)

YTD Earnings: $2.7 billion (+21%)

Comments: Worldwide pharmaceutical sales were $3.9 billion (-4%).
Depakote sales were down 75% to $102 million due to generic competition. Humira sales were $1.3 billion (+20%). Kaletra sales were $343 million (-4%). TriCor/Trilipix sales were $336 million (+9%). Lupron sales were up 28% to $197 million. Worldwide vascular sales were $658 million (+34%), with U.S. vascular sales up 81% to $395 million. Earnings include a $505 million after-tax gain and ongoing contractual payments from Takeda associated with the conclusion of the TAP joint venture.

Sign up today for Contracting & Outsourcing 2009!
dhruv_cp.rodpub.com/2009conference